Mimedx Group Overview
Valuation check: MDXG's ROE is 2.89%, below the Industrials sector average of 20.56%.
Get informed when a big investor buys or sells
+ Follow2.89%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Mimedx Group (MDXG) currently reports a ROE of 2.89%. That is below the Industrials sector average of 20.56%. Use the charts on this page to explore Mimedx Group's ROE history and peer comparisons.
Mimedx Group's ROE of 2.89% is lower than the Industrials sector average of 20.56%. That is roughly 86.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Mimedx Group's current 2.89% should be judged against Industrials norms (sector average: 20.56%) and against MDXG's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 2.89%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Industrials average is 20.56%. From there, open related valuation or income-statement pages for Mimedx Group, and consider following MDXG for alerts when major investors trade the stock.
Mimedx Group is classified in the Industrials sector. On ROE, it currently shows 2.89% versus a sector average near 20.56%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing MDXG with unrelated industries.
